XOMA Royalty Corporation (XOMA)

Over the last six months, XOMA Royalty Corp.'s stock price has decreased. Thomas Burns stepped down as Senior Vice President, Finance, and Jeffrey Trigilio was appointed as the new Chief Financial Officer in January 2026. In December 2025, XOMA Royalty and Takeda executed a royalty sharing transaction and amended an existing agreement for mezagitamab, the company announced an agreement to acquire Generation Bio Co., the acquisition of Mural Oncology plc was completed, and Rezolute Bio reported that its Phase 3 trial for ersodetug failed to meet its primary endpoint. XOMA Royalty Corporation filed a follow-on equity offering in October 2025. XOMA Royalty announced acquisitions of Turnstone Biologics, LAVA Therapeutics, and HilleVax in August 2025. XOMA Royalty entered into a definitive merger agreement to acquire Turnstone Biologics in June 2025.

XOMA Royalty Corp.'s revenue streams are tied to the sales of pharmaceutical products commercialized by its partners and the demand for royalty financing. Demand for pharmaceutical products is generally less subject to strong seasonal fluctuations. The demand for royalty financing is driven by the funding needs of biotech companies and the overall investment climate in the life sciences sector.

XOMA Royalty Corp. operates as a biotechnology royalty aggregator, acquiring and managing royalty interests and milestone payments from pharmaceutical and biotechnology products. Established in 2017, XOMA benefits from the success of therapies without the risks of drug development. As of early 2025, the company had over 120 assets, with 11 in Phase 3 development. Key assets include VABYSMO, OJEMDA, MIPLYFFA, IXINITY, XACIATO, DSUVIA, ersodetug, AFM13 and AFM24, mezagitamab, seralutinib and Ovaprene.

XOMA Royalty Corporation operates primarily in the United States and the Asia Pacific, maintaining a market presence through strategic partnerships and royalty rights acquisitions from biopharmaceutical companies worldwide.

XOMA Royalty Corp.'s brand reputation has been influenced by strategic activities and market perceptions. News headlines have reflected varying investor sentiment. A clinical trial setback for ersodetug negatively affected reputation. XOMA's strategy of acquiring and liquidating distressed biotechs has mixed reputational implications. Consistent efforts to expand its portfolio through strategic acquisitions and licensing deals are generally viewed as positive.

XOMA Royalty Corp.'s ownership is primarily composed of institutional investors, who hold approximately 46.05% of the company's stock. Insiders own about 13.18%, while public companies and individual investors account for 8.01%. Major institutional owners include BVF Partners LP Il, Fidelity Contrafund, Vanguard, Vanguard Index Funds, iShares, Morgan Stanley Insight Fund, and Morgan Stanley Institutional Fund Inc. Notable individual owners include Michael Rockefeller and Owen Hughes.